10 Best Mid Cap Pharma Stocks to Buy

5. Lantheus Holdings Inc. (NASDAQ:LNTH)

Market Capitalization as of July 22: $4.95 billion

Number of Hedge Fund Holders: 43

Lantheus Holdings Inc. (NASDAQ:LNTH) is one of the best mid cap pharma stocks to buy. On July 22, Lantheus Holdings announced the completion of its acquisition of Life Molecular Imaging Ltd./LMI, which is a subsidiary of Life Healthcare Group Holdings Ltd. As a result of this acquisition, Dr. Ludger Dinkelborg, formerly CEO and Managing Director of LMI, has been appointed as the Head of Research and Development at Lantheus, effective August 1 this year.

In his new role, Dr. Dinkelborg will oversee Clinical Development, Regulatory Affairs, Clinical Operations, Program Management, and AI/Biomarkers Solutions, reporting directly to the CEO. This acquisition brings Neuraceq (florbetaben F18 injection) into Lantheus’s portfolio. Neuraceq is a globally approved F-18 PET imaging agent used to detect beta-amyloid plaques in adults being evaluated for Alzheimer’s disease and other causes of cognitive decline, as well as for selecting patients indicated for amyloid beta-directed therapy.

The FDA approved Neuraceq on June 23 this year. The transaction also provides Lantheus with a robust commercial infrastructure for Alzheimer’s disease radiodiagnostics, advanced R&D capabilities, and an established international presence. Important safety information regarding Neuraceq includes risks for image interpretation errors and other potential inaccuracies.

Lantheus Holdings Inc. (NASDAQ:LNTH) develops, manufactures, and commercializes diagnostic and therapeutic products that assist clinicians in the diagnosis and treatment of heart, cancer, and other diseases worldwide.